Ocean Biomedical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ocean Biomedical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($9.48M) | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | ($3.70M) | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | ($114.47M) | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | ($17.36M) | Nov 25, 2024 |
| FY2022 | Dec 31, 2021 | ($564.1K) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.80M) | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | ($10.21M) | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | ($16.12M) | Nov 25, 2024 |
| FY2022 | Dec 31, 2021 | ($566.6K) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $26.0K | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | $709.0K | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | $8.41M | Nov 25, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.18M) | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | ($1.73M) | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | ($9.43M) | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | ($993.0K) | Nov 25, 2024 |
| FY2022 | Dec 31, 2021 | ($794.4K) | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $902.0K | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | $5.50M | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | $1.84M | Nov 25, 2024 |
| FY2022 | Dec 31, 2021 | $108.65M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $98.52M | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | $97.39M | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | $96.26M | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | $12.66M | Nov 25, 2024 |
| FY2022 | Dec 31, 2021 | $3.40M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($97.62M) | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | ($96.26M) | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | ($90.76M) | Apr 8, 2025 |
| FY2024 | Dec 31, 2022 | ($10.82M) | Apr 8, 2025 |
| FY2023 | Dec 31, 2021 | ($6.66M) | Nov 25, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($205.54M) | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | ($203.99M) | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | ($196.06M) | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | ($81.59M) | Nov 25, 2024 |
| FY2022 | Dec 31, 2021 | ($564.1K) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Jan 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | (4) | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Nov 25, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 8, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | (4) | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Nov 25, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 34.87M | Apr 8, 2025 |
| FY2024 | Dec 31, 2023 | 34.65M | Apr 8, 2025 |
| FY2023 | Dec 31, 2022 | 23.36M | Nov 25, 2024 |